SARAH

44 years old

Married with 2 children

Accountant

Passionate about gardening

This is a hypothetical patient profile.

IDENTIFYING APPROPRIATE PATIENTS FOR AVMAPKI™ FAKZYNJA™ CO-PACK

DIAGNOSIS: Stage III *KRAS*-mutated LGSOC (3 years ago)

- Confirmed by histopathologic exam of tissue removed during debulking surgery
- *KRAS* mutation confirmed by NGS testing; ER+ confirmed by IHC
- Negative germline testing
- Molecular profile was ordered of tumor sample from debulking surgery

RECURRENCE DETECTED BY:

- Patient reported bloating and pelvic pain
- Tumor marker CA-125 elevated
- CT scan showing nodules along pelvic peritoneum

CA, cancer antigen; CT, computed tomography; ER+, estrogen receptor-positive; IHC, immunohistochemistry; NGS, next generation sequencing.

INDICATION

AVMAPKI FAKZYNJA CO-PACK is indicated for the treatment of adult patients with *KRAS*-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

- **Ocular Toxicities:** Ocular toxicities, including visual impairment and vitreoretinal disorders, occurred. Perform comprehensive ophthalmic evaluation at baseline, prior to cycle 2, every three cycles thereafter, and as clinically indicated. Withhold AVMAPKI FAKZYNJA CO-PACK for ocular toxicities until improvement at the same or reduced dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for any grade 4 toxicity.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

AVMAPKI™ FAKZYNJA™ CO-PACK
(avutometinib capsules; defactinib tablets) 0.8 mg; 200 mg

SARAH'S TREATMENT HISTORY

Primary debulking surgery

4 WEEKS POST-SURGERY

6 cycles of carboplatin plus paclitaxel for 5 months

Maintenance hormone therapy (letrozole)

She experienced common side effects from her initial therapy, which were managed by her HCP.

FIRST RECURRENCE

25 MONTHS POST-CHEMOTHERAPY

Not a candidate for debulking surgery, not on warfarin, no active skin disorder, no ocular disorder, not pregnant, not breastfeeding.

Sarah may be an appropriate candidate for AVMAPKI FAKZYNJA CO-PACK

The first treatment specifically approved for women with *KRAS*-mutated recurrent LGSOC who have received prior systemic therapy[1]

CONSIDERATIONS FOR STARTING TREATMENT[1]

- A comprehensive ophthalmic exam at baseline, prior to cycle 2 and every 3 cycles thereafter, regardless of baseline exam findings, and as clinically indicated
- Prophylactic medications for skin reactions administered with initiation of and during at least the first 2 cycles*
- Limit unnecessary exposure to sunlight and apply sunscreen with SPF ≥30
- Monitor liver function tests prior to each cycle, on day 15 of the first 4 cycles, and as clinically indicated
- Monitor CPK prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated
- Verify pregnancy status and advise use of effective contraception

*Topical corticosteroid (applied to the face, scalp, neck, upper chest, and upper back) and systemic oral antibiotics.
CPK, creatine phosphokinase; SPF, sun protection factor.

IMPORTANT SAFETY INFORMATION (CONT'D)

Warnings and Precautions (cont'd)

- **Serious Skin Toxicities:** Skin toxicities, including photosensitivity and severe cutaneous adverse reactions (SCARs), occurred. Adhere to concomitant medications. Monitor for skin toxicities and interrupt, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity, tolerability and duration.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

AVMAPKI™ FAKZYNJA™ CO-PACK
(avutometinib capsules; defactinib tablets) 0.8 mg; 200 mg

IMPORTANT SAFETY INFORMATION (CONT'D)

Warnings and Precautions (cont'd)

- **Hepatotoxicity:** Monitor liver function tests prior to each cycle, on day 15 of the first 4 cycles, and as clinically indicated. Withhold, reduce or discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and persistence of abnormality.
- **Rhabdomyolysis:** Monitor creatine phosphokinase prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated. If increased CPK occurs, evaluate patients for rhabdomyolysis or other causes. Withhold, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and duration of the adverse reaction.
- **Embryo-Fetal Toxicity:** AVMAPKI FAKZYNJA CO-PACK can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.

Adverse Reactions

The most common (≥ 25%) adverse reactions, including laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count.

Drug Interactions

- **Strong and moderate CYP3A4 inhibitors:** Avoid concomitant use with AVMAPKI FAKZYNJA CO-PACK.
- **Strong and moderate CYP3A4 inducers:** Avoid concomitant use with AVMAPKI FAKZYNJA CO-PACK.
- **Warfarin:** Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with warfarin and use an alternative to warfarin.
- **Gastric acid reducing agents:** Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with proton pump inhibitors (PPIs) or H2 receptor antagonists. If use of an acid-reducing agent cannot be avoided, administer FAKZYNJA 2 hours before or 2 hours after the administration of a locally acting antacid.

Use in Specific Populations

- **Lactation:** Advise not to breastfeed.
- **Fertility:** May impair fertility in males and females.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

Reference: 1. AVMAPKI FAKZYNJA CO-PACK. Prescribing Information. Verastem, Inc. 2025.

VERASTEM

AVMAPKI™ FAKZYNJA™ CO-PACK
(avutometinib capsules; defactinib tablets) 0.8 mg; 200 mg